Jonathan Gertler was interviewed by the Boston Business Journal around Biogen’s strategic direction. In “Timed release: A potential inflection point nears for Biogen,” the Boston Business Journal looked at Biogen’s “ambitious transformation: to become the dominant player in the risky and increasingly competitive field of neuroscience drugs.”
Jonathan Gertler was quoted this week in an article that appeared in the Boston Globe about the end of the IPO drought in Massachusetts. Investors are again looking at healthcare – and being more cautious and selective, according to the piece.
“GE’s decision last year to move its headquarters to Boston, plus the promotion of its top health care executive, means the company likely wants to stay focused on health care,” Back Bay CEO and Founder Jonathan Gertler told the Boston Globe about GE’s announcement on June 12th that health care chief John Flannery was promoted to chief executive.
By: Greg Benning and Christopher Leo, PhD
Years past brought “bubbles” in biopharma. Our view, shared by most, is that BioPharma as an industry has evolved so substantially that even with economic vagaries and political tumult, that we are here to stay – robust, and vital to the world’s health and the world’s economy.
Atopic dermatitis – set to outpace psoriasis as the largest dermatology market?
Atopic dermatitis (AD), historically a market with few approved drugs and dominated by low priced generic treatments, is expected to undergo a revolution as a result of recent events:
Back Bay Life Science Advisors CEO Jonathan Gertler will moderate a panel discussion about corporate strategy around precision medicine at The Convergence Forum, the annual ideas exchange that brings together high-level life science leaders from around New England.